Publication | Closed Access

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

Node-positive Breast CancerBreast OncologyOncologyAdjuvant DocetaxelBcirg 001Breast CancerPharmacotherapyCancer TreatmentMedicineRadiation Oncology